These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Gallium-68-prostate-specific membrane antigen ( van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [TBL] [Abstract][Full Text] [Related]
23. PSA-stratified detection rates for [ Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527 [TBL] [Abstract][Full Text] [Related]
24. The impact of [ Frenzel T; Tienken M; Abel M; Berliner C; Klutmann S; Beyersdorff D; Schwarz R; Krüll A; Bannas P Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670 [TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
30. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093 [TBL] [Abstract][Full Text] [Related]
31. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
32. Fine-tuning of the automated [ Shamni O; Nebeling B; Grievink H; Mishani E J Labelled Comp Radiopharm; 2019 May; 62(6):252-258. PubMed ID: 30941793 [TBL] [Abstract][Full Text] [Related]
33. A Comparative Study of Gupta M; Choudhury PS; Hazarika D; Rawal S World J Nucl Med; 2017; 16(3):186-191. PubMed ID: 28670175 [TBL] [Abstract][Full Text] [Related]
34. Validation of HPLC method for the determination of chemical andradiochemical purity of a UĞur A; ElÇİ ŞG; YÜksel D Turk J Chem; 2021; 45(1):26-34. PubMed ID: 33679149 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
37. Automated synthesis and quality control of [ Aalbersberg EA; van Andel L; Geluk-Jonker MM; Beijnen JH; Stokkel MPM; Hendrikx JJMA EJNMMI Radiopharm Chem; 2020 May; 5(1):10. PubMed ID: 32358637 [TBL] [Abstract][Full Text] [Related]
38. Comparison of standard and delayed imaging to improve the detection rate of [ Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856 [TBL] [Abstract][Full Text] [Related]
39. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. Bouvet V; Wuest M; Jans HS; Janzen N; Genady AR; Valliant JF; Benard F; Wuest F EJNMMI Res; 2016 Dec; 6(1):40. PubMed ID: 27142881 [TBL] [Abstract][Full Text] [Related]
40. Simultaneous Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]